Cargando…

Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States

COVID-19 vaccines have been rapidly developed. However, widespread uptake remains a hurdle to a successful pandemic response. A simple, user-friendly survey to measure vaccine hesitancy may facilitate development of interventions aimed at maximizing vaccination. We developed a novel 10-item instrume...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrin, Matthew L., Emmerich, Veronica K., Ip, Edward H., Feldman, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428594/
https://www.ncbi.nlm.nih.gov/pubmed/36058793
http://dx.doi.org/10.1016/j.vaccine.2022.08.062
_version_ 1784779152740581376
author Hrin, Matthew L.
Emmerich, Veronica K.
Ip, Edward H.
Feldman, Steven R.
author_facet Hrin, Matthew L.
Emmerich, Veronica K.
Ip, Edward H.
Feldman, Steven R.
author_sort Hrin, Matthew L.
collection PubMed
description COVID-19 vaccines have been rapidly developed. However, widespread uptake remains a hurdle to a successful pandemic response. A simple, user-friendly survey to measure vaccine hesitancy may facilitate development of interventions aimed at maximizing vaccination. We developed a novel 10-item instrument designed to measure COVID-19 vaccine hesitancy in adults in the United States. We recruited 232 participants through Amazon’s Mechanical Turk, an online crowdsourcing platform. The internal consistency (Cronbach’s α = 0.89) and temporal stability (r = 0.87; p < 0.001) of our survey was strong. Lower hesitancy (high scores) was associated with higher trust in physicians (r = 0.58; p < 0.001), and higher hesitancy (low scores) was reported with higher belief in conspiracies (r = -0.68; p < 0.001). The correlation between low hesitancy and reported intent to receive (or history of receiving) at least one dose of the COVID-19 vaccine was moderate-strong (r = 0.68; p < 0.001).
format Online
Article
Text
id pubmed-9428594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-94285942022-08-31 Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States Hrin, Matthew L. Emmerich, Veronica K. Ip, Edward H. Feldman, Steven R. Vaccine Short Communication COVID-19 vaccines have been rapidly developed. However, widespread uptake remains a hurdle to a successful pandemic response. A simple, user-friendly survey to measure vaccine hesitancy may facilitate development of interventions aimed at maximizing vaccination. We developed a novel 10-item instrument designed to measure COVID-19 vaccine hesitancy in adults in the United States. We recruited 232 participants through Amazon’s Mechanical Turk, an online crowdsourcing platform. The internal consistency (Cronbach’s α = 0.89) and temporal stability (r = 0.87; p < 0.001) of our survey was strong. Lower hesitancy (high scores) was associated with higher trust in physicians (r = 0.58; p < 0.001), and higher hesitancy (low scores) was reported with higher belief in conspiracies (r = -0.68; p < 0.001). The correlation between low hesitancy and reported intent to receive (or history of receiving) at least one dose of the COVID-19 vaccine was moderate-strong (r = 0.68; p < 0.001). Elsevier Ltd. 2022-09-22 2022-08-31 /pmc/articles/PMC9428594/ /pubmed/36058793 http://dx.doi.org/10.1016/j.vaccine.2022.08.062 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Hrin, Matthew L.
Emmerich, Veronica K.
Ip, Edward H.
Feldman, Steven R.
Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title_full Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title_fullStr Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title_full_unstemmed Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title_short Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States
title_sort development and validation of a covid-19 vaccine hesitancy scale for adults in the united states
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428594/
https://www.ncbi.nlm.nih.gov/pubmed/36058793
http://dx.doi.org/10.1016/j.vaccine.2022.08.062
work_keys_str_mv AT hrinmatthewl developmentandvalidationofacovid19vaccinehesitancyscaleforadultsintheunitedstates
AT emmerichveronicak developmentandvalidationofacovid19vaccinehesitancyscaleforadultsintheunitedstates
AT ipedwardh developmentandvalidationofacovid19vaccinehesitancyscaleforadultsintheunitedstates
AT feldmanstevenr developmentandvalidationofacovid19vaccinehesitancyscaleforadultsintheunitedstates